Abstract
The proteome is an abundant source of potential therapeutic targets, and a comprehensive evaluation of proteins as therapeutic targets for a wide range of diseases is required. By screening 4,907 plasma proteins, we conducted a systematically two-sample proteome-wide Mendelian randomisation (MR) study to uncover potential therapeutic targets for 18 clinical diseases. Following MR analysis and stringent process filtering, a total of 146 causative plasma proteins (false discovery rate<0.05) were discovered. Colocalization analysis (Posterior Probability H4>0.8) further supported the causality of three proteins (MAP2K1, GFRA1, and THBS3) in gastroesophageal reflux disease; LYPLAL1 in keratoconus; three proteins (PCSK9, ANGPTL4, and GCKR) in familial hyperlipidemia; CRAT in atopic eczema; three proteins (IRF3, CA12, and TNFRSF1B) in hypothyroidism; AIF1 in age-related hearing impairment; SCARF2 in male pattern baldness; IRF3 in basal cell carcinoma; and four proteins (RPS6KA1, ULK3, MPPED2, and BTN3A1) in prostate cancer. Interestingly, having a genetically higher circulating CA12 level is associated with a lower risk of hypothyroidism (OR=0.47, p-value=1.68e-05, Posterior Probability H4=0.82). Single-cell RNA sequencing analysis showed that CA12 was mainly expressed in fibroblasts and epithelial cells in patient thyroid tissue and that its expression increased in older adults. Furthermore, with a proportion of 3.8%, hypothyroidism appears to mediate the effect of IRF3 on idiopathic pulmonary fibrosis, according to mediation analysis. Overall, our research could provide new insights into the etiology of clinical diseases as well as intriguing targets for the development of screening biomarkers and therapeutic treatments.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The results of proteome-wide Mendelian randomisation and colocalization analyses for prostate cancer and basal cell carcinoma have been added to the manuscript.
Data Availability
All the data produced in the present work is contained in the manuscript
